Informations générales (source: ClinicalTrials.gov)
Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
Interventional
N/A
Institut Claudius Regaud (Voir sur ClinicalTrials)
août 2025
novembre 2026
28 mai 2026
This trial is a pilot, prospective, single-center study conducted in a population of
patients with metastatic breast cancer (whatever the immunohistochemical subtype) or
metastatic prostate cancer. The aim of this exploratory study is to compare the
sensitivity of three different techniques (CellSearch®, Parsortix® and SmartCatch®) in
detecting circulating tumor cells (CTCs). After the patient's agreement, and before
starting anti-tumor treatment, a blood sample will be taken using the 3 different CTC
detection techniques.
Each patient will participate in the study for one day.
A total of 54 evaluable patients (36 patients with metastatic breast cancer and 18
patients with metastatic prostate cancer) will be included in this interventional study.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| IUCT-O - Toulouse - France | Florence DALENC | Contact (sur clinicalTrials) | |||
Critères
Tous
1. Patient with breast cancer (whatever the immunohistochemical subtype:
triple-negative, RH+/HER2-negative or HER2-positive) or prostate cancer,
multi-metastatic, eligible for a new line of treatment.
2. Patient not yet initiated on a new specific treatment for breast or prostate cancer
at inclusion.
3. Age ≥ 18 years and WHO ≤ 2
4. Patient affiliated to Social Security scheme in France.
5. Patient having signed informed consent prior to inclusion in the study and prior to
any study-specific procedures.
Exclusion Criteria:
1. Associated pathology(ies) likely to prevent the study procedure from running
smoothly
2. Any psychological, family, geographical or sociological condition that prevents
compliance with the medical follow-up and/or procedures stipulated in the study
protocol.
3. Patient deprived of liberty or under legal protection (guardianship, legal
protection)
4. Patient who has had another solid tumor (excluding carcinoma in situ of the breast
or cervix) within 5 years.